Drug Search Results

Latrepirdine

Alternative Names: latrepirdine, dimebon, pf-01913539, pf01913539, pf 01913539, pf-1913539, pf1913539, pf 1913539
Latest Update: 2024-09-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT6 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Russia

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Latrepirdine

Countries in Clinic: Russia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Alzheimer Disease

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
DMBN_ALZH-2022-II	P2	Active, not recruiting	Alzheimer Disease	2024-12-21

Recent News Events

Date	Type	Title
01/09/2024	PubMed	In-silico Design, ADMET Screening, Prime MM-GBSA Binding Free Energy Calculation and MD Simulation of Some Novel Phenothiazines as 5HT6R Antagonists Targeting Alzheimer's Disease.
06/24/2023	PubMed	Design, Synthesis, Molecular Docking Study and Biological Evaluation of Novel gamma-Carboline Derivatives of Latrepirdine (Dimebon) as Potent Anticancer Agents.
01/01/2023	PubMed	Targeting mitochondrial dysfunction to salvage cellular senescence for managing neurodegeneration.
05/19/2020	News Article	TauRx Reveals Study Results That Offers New Hope for Treatment of Patients With Dementia
05/19/2020	News Article	TauRx Reveals Study Results That Offers New Hope for Treatment of Patients With Dementia

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions